DEPLOYDatabase

Company

Medtronic

surgical robotmedtronic.com

Medtronic (NYSE: MDT) is a global medical device company developing surgical robotics (Hugo RAS system), cardiac devices, and neurostimulation.

Track Medtronic
Founded
1949
HQ
Dublin, Ireland
Status
Public

The verified answer

As of Oct 2026, DEPLOY verifies Medtronic: 1 model, 6 deployments across 4 regions, 7 active incidents. 5 sources back the record.

Regulatory status2 FDA 510(k) clearances1 FDA De Novo authorization

Medtronic holds 2 FDA 510(k) clearances and 1 FDA De Novo authorization, per the DEPLOY registry.

See all 3 filings
PublicNYSE: MDT

CategorySurgical robots

Models

1

Deployments

6

Overview

Medtronic (NYSE: MDT) is a global medical device company developing surgical robotics (Hugo RAS system), cardiac devices, and neurostimulation. The Hugo robotic-assisted surgery platform competes with Intuitive surgical's da Vinci. Makes strategic investments via Medtronic Ventures in surgical robotics and digital health.

Reality check

Cornerstone Robotics deal (company-claimed, Sep 2026)

About $700M strategic investment; rights to distribute the Sentire surgical robot outside the US with Hugo.

Verified record

Verified deployments
6 deployments on file
Active incidents
7 incidents on file

Key facts

Product

Hugo RAS modular multi-port teleoperated surgical robot.

Gating events

CE mark Oct 2021; US FDA urology clearance Dec 3 2025 (urology only).

Stock listing

NYSE: MDT

Company type

Global medical-device company

Market positioning

Hugo RAS is positioned as a late-market challenger to da Vinci in robotic-assisted surgery

Stocksee public companies →

NYSE: MDT

Surgical robotics

Hugo RAS, robotic-assisted surgery platform

Competitor

Intuitive Surgical da Vinci

Data & sources

Press releases

2

Web sources

3

5 sources backing this record.View all →

Relationships

PPublic MarketInvestorMMedtronicCustomer

Explainers

Plain-language answers to the questions people ask about Medtronic, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.

What is a surgical robot?
A surgical robot is a computer-assisted operative platform that places robotic arms, instruments, and visualization systems between the surgeon and the patient. The 2026 commercial cohort includes Intuitive Surgical (da Vinci + Ion; 11,395 + 1,041 systems installed per SEC 10-Q), Medtronic Hugo, CMR Surgical Versius, Asensus/Karl Storz Senhance, Stereotaxis Genesis, Distalmotion Dexter, Moon Surgical Maestro (ScoPilot is the cohort's genuine shipped surgical AI standout, FDA-cleared with a Predetermined Change Control Plan), and Brain Navi NaoTrac (autonomous registration, not tissue manipulation). J&J Ottava (De Novo submission January 2026) and Vicarious Surgical V1 remain pre-market research per DEPLOY's FDA-clearance-as-gating-event framework. The autonomy spectrum runs from teleoperated baseline through analytics AI to narrow autonomous registration; tissue-manipulation autonomy remains research demos on production hardware, not shipped product.Read the full explainer →
What is Medtronic Hugo?
Medtronic Hugo is the Hugo RAS (Robotic-Assisted Surgery) modular soft-tissue surgical system from Medtronic (NYSE: MDT). Per DEPLOY's surgical cluster framework: FDA IDE (Investigational Device Exemption) pivotal trial pathway US state (current submission posture operates at cap-flag pending primary-source verification); commercial in CE-Mark regions across EU + select international markets. Editorial throughline: large-prime IDE-pivotal pathway archetype within the surgical cluster's FDA-clearance-posture axis, contrasting Intuitive da Vinci market-leader cleared multi-procedure + J&J Ottava De Novo pre-market + CMR Versius international commercial soft-tissue. Hugo closes the Wave 1 surgical FDA-clearance triangle (Intuitive market-leader + Hugo IDE-pivotal + Ottava De Novo pre-market) that was the original framework's third leg missing from news anchors prior to this Wave 3 backfill.Read the full explainer →
What is the cheapest surgical robot?
Distalmotion's Dexter, at roughly $500K-$1M (2025 analyst estimate), is the cheapest FDA-cleared general soft-tissue surgical robot on record, undercutting da Vinci ($1.5M-$2.5M) and Versius ($750K-$1M).Read the full explainer →

Current leadership (5)

Board (1)

Media (1)

Company-anchored media. Official assets the company has published at the company level, distinct from model-anchored media that lives on individual product pages.

Safety record

7 incidents on record (2 serious, 3 moderate, 2 minor). Most recent: Jul 2026.

serious
2
moderate
3
minor
2
regulatory action
3
malfunction
3
injury
1

Most recent: Jul 2026

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Incidents affecting Medtronic (7)

Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.

Operator customers (1)

Recent coverage

Medtronic in third-party press

2026 State of Business Readiness: Bill Koschak

Oct 5, 2026

Medtronic (MDT) Raises its Outlook Again as Heart Device Demand Keeps Climbing

Sep 17, 2026

A former Medtronic and J&J engineer shares his mission-driven purpose

Sep 16, 2026

Peers

43 peers across 1 segment. Every Medtronic competitor derived from shared form-factor and application-domain edges.

surgical robot(43)

28 companies in this segment · moderately_concentrated (HHI 2056.2102191459944) · leader Mazor Robotics at 3317%

Mentioned on (36)

Registry pages whose text names Medtronic.